m6A RNA methylation regulator-based signature for prognostic prediction and its potential immunological role in uterine corpus endometrial carcinoma

BMC Cancer

Research

Haoyu Huang¹  Fang Fang¹  Xiaocen Liu²  Mingquan Ye³  Peipei Wang³  Qingqing Li³ 

[1] Department of Laboratory Medicine, Yijishan Hospital, the First Affiliated Hospital of Wannan Medical College, 241001, Wuhu, China;Anhui Province Clinical Research Center for Critical Respiratory Medicine, Yijishan Hospital, the First Affiliated Hospital of Wannan Medical College, 241001, Wuhu, China;Department of Nuclear medicine, Yijishan Hospital, the First Affiliated Hospital of Wannan Medical College, 241001, Wuhu, China;School of Medical Information, Wannan Medical College, 241001, Wuhu, China;Research Center of Health Big Data Mining and Applications, Wannan Medical College, 241001, Wuhu, China;

关键词: UCEC;    m6A RNA methlation;    Prognostic prediction;    Gene signature;   

DOI  :  10.1186/s12885-022-10490-x

 received in 2022-07-07, accepted in 2022-12-26,  发布年份 2022

来源: Springer

【 摘 要 】

BackgroundUterine corpus endometrial carcinoma (UCEC) is the most common female pelvic malignancy worldwide. N6-methyladenosine (m6A) plays an important role in various cellular responses, especially in cancer progression. However, the correlation between prognostic UCEC and m6A RNA methylation regulators remains unclear.MethodsWe used The Cancer Genome Atlas (TCGA) to provide a gene signature that could improve the prognostic evaluation of UCEC patients according to the distinct genetic trait of m6A RNA methylation regulators from a bioinformatics perspective. After comparing UCEC subgroups with different genetic profiles of m6A regulators, we identified 71 differentially expressed genes associated with overall survival (OS) and generated a nine-gene signature through least absolute shrinkage and selection operator (LASSO) Cox regression analysis. Finally, we used in vitro and in vivo tumor cell experiments as well as the immune correlation analysis to verify the function of each gene in the proposed gene signature.ResultsTime-dependent receiver operating characteristic (ROC) curves revealed that the proposed gene signature could predict the outcome of UCEC patients accurately. We found that CDKN2A mainly acted from the perspective of tumor cells, while COL4A4, PXDN, TIGIT, CHODL, LMO3, KCNJ12, L1CAM, and EPHB1 might play a role in UCEC from an immunological point of view.ConclusionsFrom an epigenetics perspective, the m6A RNA methylation regulator-based gene signature can predict the prognosis of UCEC patients and immune therapeutic efficacy.

【 授权许可】

CC BY   
© The Author(s) 2022

【 图 表 】

Fig. 1

40249_2022_1045_Article_IEq27.gif

40249_2022_1045_Article_IEq10.gif

Fig. 1

Fig. 4

Fig. 1

Fig. 3

Fig. 1